This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. CALT, ZYME, SBTX, MBX, AVTE, NLTX, BIOA, CYBN, VIRI, and WHWKShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). Aquinox Pharmaceuticals vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics Aquinox Pharmaceuticals (NASDAQ:AQXP) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation. Which has higher valuation & earnings, AQXP or CALT? Aquinox Pharmaceuticals has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M16.43-$31.58MN/AN/ACalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Which has more volatility & risk, AQXP or CALT? Aquinox Pharmaceuticals has a beta of -7.37, suggesting that its stock price is 837% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Do insiders and institutionals believe in AQXP or CALT? 71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor AQXP or CALT? In the previous week, Calliditas Therapeutics AB (publ) had 1 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 1 mentions for Calliditas Therapeutics AB (publ) and 0 mentions for Aquinox Pharmaceuticals. Aquinox Pharmaceuticals' average media sentiment score of 0.00 beat Calliditas Therapeutics AB (publ)'s score of -0.71 indicating that Aquinox Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Aquinox Pharmaceuticals Neutral Calliditas Therapeutics AB (publ) Negative Is AQXP or CALT more profitable? Aquinox Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% SummaryAquinox Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 7 of the 11 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$410.77M$839.18M$5.70B$10.27BDividend YieldN/A4.84%5.72%4.60%P/E RatioN/A1.1875.8126.51Price / Sales16.4326.63492.95166.26Price / CashN/A19.5625.8129.90Price / Book5.656.6612.836.31Net Income-$31.58M-$4.13M$3.28B$270.12M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$17.45-8.2%N/A-54.7%$410.77M$25M0.008CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.4951 of 5 stars$15.23+0.3%$21.43+40.7%+27.0%$1.14B$122.87M-10.15460Positive NewsSBTXSilverback TherapeuticsN/A$10.70+6.3%N/A-24.6%$385.82MN/A-4.4283High Trading VolumeMBXMBX Biosciences2.8203 of 5 stars$11.42+4.8%$37.63+229.5%N/A$383.64MN/A-2.5236Positive NewsAVTEAerovate TherapeuticsN/A$7.48-3.7%N/A-88.4%$216.81MN/A-2.5020Positive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.45-2.5%N/A-54.7%$182.79MN/A-6.2590High Trading VolumeBIOABioAge Labs0.2083 of 5 stars$4.98-2.2%N/AN/A$182.48MN/A0.00N/ANews CoverageCYBNCybin2.1564 of 5 stars$6.43+2.6%$85.00+1,221.9%N/A$151.68MN/A-1.4750High Trading VolumeVIRIVirios TherapeuticsN/A$4.90flat$5.00+2.0%+2,409.0%$94.36MN/A-18.155WHWKWhitehawk Therapeutics1.1759 of 5 stars$1.80+0.6%N/AN/A$84.36M$25.98M0.0021 Related Companies and Tools Related Companies CALT Competitors ZYME Competitors SBTX Competitors MBX Competitors AVTE Competitors NLTX Competitors BIOA Competitors CYBN Competitors VIRI Competitors WHWK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQXP Stock Alerts